Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 22-27

  Dietrich, Sascha ^a   Falk, Christine S ^b   Benner, Axel ^c   Karamustafa, Suzan ^a   Hahn, Esther ^a   Andrulis, Mindaugas ^d   Hegenbart, Ute ^a   Ho, Anthony D ^a   Dreger, Peter ^a   Luft, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Angiopoietin 2; IL 8; Thrombomodulin

Indexed keywords

ANGIOPOIETIN 2; CYCLOSPORIN A; INTERLEUKIN 8; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SCATTER FACTOR; STEROID; TACROLIMUS; THROMBOMODULIN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL STRESS; CELLULAR PARAMETERS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL VULNERABILITY; ENDOTHELIUM INJURY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; STEROID THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERLEUKIN-8; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOMODULIN; TRANSPLANTATION, HOMOLOGOUS; VESICULAR TRANSPORT PROTEINS;

EID: 84871893930     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.09.018     Document Type: Article

References (29)

1. Parmar S., Fernandez-Vina M., de Lima M. Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia. Curr Opin Hematol 2011, 18:98-104.
2. Ferrara J.L., Levine J.E., Reddy P., et al. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
4. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
5. Schmitt T., Luft T., Hegenbart U., et al. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011, 46:580-585.
6. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
7. Westin J.R., Saliba R.M., De Lima M., et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011, 2011:601953.
8. Andrulis M., Dietrich S., Longerich T., et al. Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease. Haematologica 2012, 97:1674-1677.
9. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
10. Zhang J., Defelice A.F., Hanig J.P., et al. Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol 2010, 38:856-871.
11. Nishimura M., Ushiyama M., Nanbu A., et al. Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens 1997, 15:1137-1142.
12. Nishimura M., Ushiyama M., Nanbu A., et al. Vascular endothelium-related factors and atherosclerosis/arteriosclerosis: serum hepatocyte growth factor as a possible indicator of vascular lesions. Rinsho Byori 1998, 46:671-677. (in Japanese).
13. Rajpathak S.N., Wang T., Wassertheil-Smoller S., et al. Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. Stroke 2010, 41:857-862.
14. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
15. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
16. Ruan P.K., Gray R.J. Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 2008, 27:5709-5724.
17. Fine J., Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
18. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
19. Isermann B., Sood R., Pawlinski R., et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003, 9:331-337.
20. Zhang J., Hanig J.P., De Felice A.F. Biomarkers of endothelial cell activation: candidate markers for drug-induced vasculitis in patients or drug-induced vascular injury in animals. Vascul Pharmacol 2012, 56:14-25.
21. Levine J.E., Logan B.R., Wu J., et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012, 119:3854-3860.
22. Harris A.C., Ferrara J.L., Braun T.M., et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119:2960-2963.
23. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
24. Salat C., Holler E., Kolb H.J., et al. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997, 19:909-914.
25. Biedermann B.C., Tsakiris D.A., Gregor M., et al. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplant 2003, 32:1077-1084.
26. Ertault-Daneshpouy M., Leboeuf C., Lemann M., et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood 2004, 103:4681-4684.
27. Palomo M., Diaz-Ricart M., Carbo C., et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010, 16:985-993.
28. Penack O., Socie G., Van den Brink M.R. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011, 117:4181-4189.
29. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.